Order Paroxetine Online - Australian Pharmacy

Depressive disorders and anxiety-related conditions frequently present with persistent low mood, diminished interest, excessive worry, sleep disturbance, and impaired daily functioning. Paroxetine is a selective serotonin reuptake inhibitor (SSRI) approved for several mood and anxiety disorders. It elevates synaptic serotonin by blocking its reabsorption in the central nervous system, thereby modulating mood and anxiety circuits.

What Paroxetine is

Paroxetine is a prescription antidepressant of the phenylpiperidine class that functions as a selective serotonin reuptake inhibitor. It primarily increases serotonin availability at central synapses, which contributes to its therapeutic effects in mood and anxiety disorders. The compound is administered orally in tablet or orally disintegrating tablet forms and is subject to hepatic metabolism with a relatively long elimination half-life.

Pharmacokinetic properties include rapid absorption and substantial first-pass metabolism, with a duration of action that supports once-daily dosing in many regimens. Paroxetine is a potent inhibitor of the cytochrome P450 2D6 enzyme, a feature that underpins several clinically relevant drug interactions. Careful consideration of hepatic function and concurrent medications is advised during therapy initiation and adjustment.

The medication is supplied in multiple formulations to accommodate patient needs, including immediate-release and extended-release preparations. Therapeutic onset commonly requires several weeks, and treatment should be continued at therapeutic doses to assess full benefit. Dose changes should be gradual to minimize withdrawal phenomena.

What it is used for

Paroxetine is indicated for major depressive disorder and various anxiety disorders. These include generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive‑compulsive disorder, and post‑traumatic stress disorder. It is also used for premenstrual dysphoric disorder in select indications.

Clinical use focuses on alleviating core symptoms such as depressed mood, excessive worry, intrusive thoughts, and avoidance behaviors. In each indication, paroxetine aims to restore functioning and quality of life by modulating serotonergic signaling in circuits involved in mood and fear response. Dosing is individualized based on diagnosis, comorbidity, and tolerability, with careful monitoring for adverse effects and mood stability.

Therapeutic response may be influenced by patient factors including age, liver function, and concomitant medications. In pediatric populations, safety and efficacy vary by indication; prescribers assess risk and benefit when considering initiation or continuation. Abrupt discontinuation is discouraged to reduce withdrawal symptoms and relapse risk.

Contraindications and precautions

Paroxetine is contraindicated in individuals with known hypersensitivity to the active substance or to any excipients. It should not be used concurrently with monoamine oxidase inhibitors (MAOIs) or within a washout period after MAOI therapy due to the potential for serotonin syndrome, a potentially life‑threatening interaction. Coadministration with linezolid or intravenous methylene blue is likewise contraindicated for the same reason.

Use during pregnancy requires careful consideration; paroxetine carries a risk of adverse fetal outcomes and persistent pulmonary hypertension of the newborn. It should be employed only if the anticipated benefit justifies the risk. Breastfeeding is generally not advised because paroxetine is excreted into breast milk and may affect a nursing infant. Alternative agents should be discussed with the clinician if breastfeeding is required.

Hyponatremia, particularly in elderly patients or those with risk factors, warrants monitoring of serum sodium. The drug can precipitate mania or hypomania in susceptible individuals, and bipolar spectrum disorders require careful diagnostic assessment before initiation. Suicidality risk remains in younger patients and those with depressive or anxiety disorders; close observation is essential during initiation and any dose change. Hepatic impairment necessitates cautious use and possible dose adjustment; severe renal impairment may alter exposure and response. Paroxetine can prolong the QT interval in susceptible individuals, especially with electrolyte disturbances or overdose, thus warranting avoidance in known long‑QT syndromes or significant electrolyte abnormalities.

Side effects by frequency

Common adverse effects include nausea, dry mouth, somnolence or insomnia, and fatigue. Sexual dysfunction, such as decreased libido or delayed ejaculation, is frequently reported and should be discussed with the clinician if it emerges. Increased sweating and headache are also observed with steady use.

Less common adverse events include dizziness, tremor, and GI disturbances beyond nausea, such as diarrhea or constipation. Appetite changes and weight fluctuations may occur. In some patients, sedation or agitation can complicate daily activities, particularly during dose initiation or adjustment.

Serious but less frequent reactions include hyponatremia, significant mood changes, severe allergic responses, serotonin syndrome with concurrent serotonergic drugs, and increased risk of bleeding with concomitant NSAIDs or anticoagulants. Discontinuation symptoms may appear if the medication is stopped abruptly, including flu-like feelings, irritability, or sensory disturbances. Any concerning or persistent adverse effects warrant prompt medical evaluation and possible dose modification.*

Interactions with other substances

Paroxetine is a potent inhibitor of CYP2D6 and is susceptible to clinically meaningful drug interactions. Co‑use with other serotonergic agents, including other SSRIs, SNRIs, TCAs, triptans, or St. John’s wort, can elevate the risk of serotonin syndrome and requires careful monitoring or avoidance.

Concomitant use with MAO inhibitors is contraindicated due to serotonin syndrome risk. Caution is advised when combining paroxetine with anticoagulants, antiplatelet agents, or NSAIDs because bleeding risk may be increased. The medication can also interact with drugs affecting hemodynamics or hepatic metabolism, necessitating dose adjustments and monitoring of clinical response and laboratory parameters.

Notable pharmacodynamic interactions include reduced effectiveness of certain drugs such as tamoxifen, where paroxetine’s CYP2D6 inhibition can lower endoxifen formation. Alcohol may enhance sedation and impairment of judgment. When initiating therapy, a comprehensive medication review is essential to identify potential interactions and to make appropriate therapeutic choices.